Document
Certain Dermatological Treatment Devices and Components Thereof II; Notice of Institution of Investigation
Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on June 22, 2026, under section 337 of the Tariff Act of 1930, as amended, on beha...
SUPPLEMENTARY INFORMATION:
Authority:
The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.10 of the Commission's Rules of Practice and Procedure, 19 CFR 210.10 (2025).
Scope of Investigation:
Having considered the complaint, the U.S. International Trade Commission, on July 22, 2026, Ordered That—
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of one or more of claims 1-8, 11-13, and 16-18 of the '536 patent; claims 13 and 14 of the '774 patent; claims 2-6, 8, 9, 13-16, and 18 of the '812 patent; and claims 1-18 of the '549 patent, and whether an industry in the United States exists as required by subsection (a)(2) of section 337;
(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the investigation, is “RF microneedling dermatological treatment devices and components thereof, including the consoles, handpieces, and needle tips”;
(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:
(a) The complainant is: Serendia, LLC, 3660 Wilshire Blvd., Suite 504, Los Angeles, CA 90010.
(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:
InMode Ltd., Tavor Building, Shaar Yokneam, P.O. Box 533, Yokneam 2069206, Israel.
Invasix Inc., 17 Hughes, Irvine, CA 92618.
BTL Industries, Inc., 362 Elm Street, Suite 5, Marlborough, MA 01752.
BTL Industries Limited, 161 Cleveland Way, Hertfordshire, Stevenage SG1 6BU, England, United Kingdom.
BTL Industries JSC, Ul. Tsar Kaloyan 8, Et. 2, 1000 Sofia, Bulgaria.
BTL Healthcare Technologies A/S, Stepanska 535/6, 12000 Prague, Czech Republic.
BTL Enterprise Group A/S, Stepanska 535/6, 12000 Prague, Czech Republic.
BTL Medical Technologies S.R.O. Evropska 423/178, 16000 Prague, Czech Republic.
BTL Holding Limited, Spyrou Kyprianoy 38, 4154 Limassol, Cyprus.
(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.
The Office of Unfair Import Investigations will not participate as a party in this investigation.
Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.
Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: July 22, 2026.
Sharon Bellamy,
Supervisory and Hearings and Information Officer.